EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus

Ryutaro Fukui, Yusuke Murakami, Atsuo Kanno, Yuji Motoi, Atsushi Manno, Tomohiro Honda, Shinnosuke Yamada, Jun Ishiguro, Takashi Kagari, Kensuke Nakamura, Michinori Kadokura, Takashi Isobe und 5 weitere

International Immunology · 2026

DOI: 10.1093/intimm/dxaf046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunology, 2026. Verfasst von Ryutaro Fukui und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Toll-Like Receptor 7, Lupus Erythematosus, Systemic, Antibodies, Monoclonal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Daiichi Sankyo Co., Ltd, JST Core Research for Evolutional Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptor 7 (TLR7) is an endosomal sensor that responds to both pathogen-derived and self-derived single-stranded RNA (ssRNA). Responses of TLR7 to self-derived ssRNA have been implicated in the development of autoimmune diseases, such as systemic lupus erythematosus (SLE). TLR7 antagonists and inhibitory anti-TLR7 monoclonal antibodies (mAbs) can protect lupus-prone NZBWF1 mice from lethal nephritis. However, less is known about TLR7 dependence and activation in human SLE, as both TLR7 and TLR8 respond to ssRNA in humans. Here, we analyzed public databases and found that TLR7 gene signature scores were consistently elevated across datasets, races, and SLEDAI scores compared to TLR8, suggesting a deeper involvement of TLR7 in SLE pathogenesis. To specifically inhibit human TLR7 responses, we developed inhibitory mAbs against human TLR7. Utilizing an inhibitory clone, we generated the humanized mAb, DS-7011a. DS-7011a effectively inhibited TLR7-mediated responses in plasmacytoid dendritic cells (pDCs) and B cells. Furthermore, DS-7011a was internalized in a TLR7-dependent manner and accumulated in B cells, pDCs, conventional dendritic cells (cDCs), and monocytes/macrophages. In this study, we describe the generation and preclinical development of DS-7011a, which has the potential to be a therapeutic option for the treatment of SLE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7Lupus Erythematosus, SystemicAntibodies, MonoclonalHumansAnimalsMiceDendritic CellsB-LymphocytesFemale

Stichwörter der Autor:innen

antibody drugautoimmunitygene signaturehumanized antibody

Substanzen

Toll-Like Receptor 7TLR7 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Innate Immunity, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan.
  • Medical Mycology Research Center, Chiba University, Chiba, Japan.
  • Faculty of Pharmacy, Department of Pharmaceutical Sciences, Research Institute of Pharmaceutical Sciences, Musashino University, Tokyo, Japan.
  • Discovery Research Laboratories II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.
  • Translational Science Department II, Daiichi Sankyo Co., Ltd., Tokyo, Japan.

ORCID-Profile: Toshiyuki Shimizu

Förderung

  • Japan Society for the Promotion of Science
  • Daiichi Sankyo Co., Ltd
  • JST Core Research for Evolutional Science and Technology
  • Joint Research Project of The Institute of Medical Science

Zitieren

APA

Fukui, R., Murakami, Y., Kanno, A., Motoi, Y., Manno, A., Honda, T., Yamada, S., Ishiguro, J., Kagari, T., Nakamura, K., Kadokura, M., Isobe, T., Tomimori, Y., Tanaka, J., Senaldi, G., Shimizu, T., & Miyake, K. (2026). Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus. International Immunology. https://doi.org/10.1093/intimm/dxaf046

Vancouver

Fukui R, Murakami Y, Kanno A, Motoi Y, Manno A, Honda T, et al. Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus. International Immunology. 2026. doi:10.1093/intimm/dxaf046

BibTeX
@article{Fukui2026,
  author = {Fukui, Ryutaro and Murakami, Yusuke and Kanno, Atsuo and Motoi, Yuji and Manno, Atsushi and Honda, Tomohiro and Yamada, Shinnosuke and Ishiguro, Jun and Kagari, Takashi and Nakamura, Kensuke and Kadokura, Michinori and Isobe, Takashi and Tomimori, Yoshiaki and Tanaka, Jun and Senaldi, Giorgio and Shimizu, Toshiyuki and Miyake, Kensuke},
  title = {Anti-human TLR7 antibody for therapeutic intervention in systemic lupus erythematosus},
  journal = {International Immunology},
  year = {2026},
  doi = {10.1093/intimm/dxaf046}
}
Kostenlos starten →